Table 1.
Contribution of patients and person-time to VTE analyses, by data source
| Data source | Country | Eligible (unmatched) patients | Patients included in analysesa | ||||
|---|---|---|---|---|---|---|---|
| Baricitinib (n) |
TNFi (n) |
Baricitinib (n) |
Baricitinib exposure (PY) |
TNFi (n) |
TNFi exposure (PY) |
||
| US data | |||||||
| Aetna/Healthagen | US | 69 | 289 | 37 | 13 | 37 | 22 |
| Anthem (HIRD) | US | 255 | 1304 | 123 | 69 | 123 | 99 |
| CorEvitas US | US | 118 | 1897 | 112 | 76 | 112 | 85 |
| HealthVerity PS20 | US | 933 | 3953 | 748 | 236 | 748 | 3785 |
| Humana | US | 89 | 154 | 49 | 20 | 49 | 21 |
| Marketscan | US | 257 | 1599 | 185 | 84 | 185 | 78 |
| MDR | US | 188 | 1686 | 114 | 61 | 114 | 70 |
| Optum® Clinformatics® | US | 348 | 1441 | 284 | 118 | 284 | 163 |
| PharMetrics Plus | US | 473 | 6576 | 261 | 141 | 261 | 159 |
| Europe and Japan data | |||||||
| ARTIS | Sweden | 1737 | 6230 | 1685 | 2314 | 1685 | 2608 |
| BKK | Germany | 851 | 3332 | 765 | 539 | 765 | 544 |
| CorEvitas JP | Japan | 210 | 354 | 171 | 200 | 171 | 248 |
| JMDC | Japan | 243 | 1721 | 213 | 154 | 213 | 115 |
| SNDS | France | 3242 | 10,202 | 2859 | 1855 | 2859 | 1923 |
| Total | 9013 | 40,738 | 7606 | 5879 | 7606 | 6512 | |
ARTIS anti-rheumatic therapy in Sweden, BKK Betriebskrankenkasse, HIRD HealthCore Integrated Research Database, JMDC JMDC, Inc.’s claims database, JP Japan, MACE major adverse cardiovascular event, MDR military health system data repository, n number of patients, Optum® Clinformatics® Optum’s de-identified Clinformatics® Data Mart Database, PS20 Private Source 20, PY person-years, SNDS Système National des Données de Santé, TNFi tumor necrosis factor inhibitor, US United States, VTE venous thromboembolism
aAvailable information on sample size (n) and baricitinib exposure (PY) among eligible propensity score-matched patients analyzed to assess risk of VTE